The Methodist DeBakey Heart & Vascular Center has been selected to participate in a clinical trial to study treatment of aortic stenosis through transcatheter aortic valve implantation (TAVI), also known as percutaneous aortic valve replacement (PAVR).
Why is this study being done?
The Methodist DeBakey Heart & Vascular Center is conducting this study to compare the results of TAVI using the Medtronic CoreValve to open-heart surgical aortic valve replacement in patients with severe symptomatic aortic stenosis in high risk patients and to objective performance criteria in extreme risk patients who are not considered candidates for surgery.
Who is eligible?
Patients eligible for this trial are people with severe aortic stenosis who are experiencing symptoms (difficulty breathing, chest pain or pressure, or fainting). The symptoms do not have to be severe but the degree of aortic stenosis does.
What will the study entail?
The procedure involves placing a new catheter-mounted aortic valve into the position where the diseased valve is located. The existing valve will not actually be replaced; rather, the new valve will be placed inside the old valve and enlarge the opening.
How can I find out more?
To learn more about the Medtronic CoreValve® U.S. Pivotal Trial at the Methodist DeBakey Heart & Vascular Center, please contact Tiffani Gray, MSN, RN, FNP-C, ACNP-BC , Study Coordinator, at 713-441-2863 or 281-952-3633 (pager), or send an email to email@example.com.
Learn more about aortic stenosis: